Gottlieb, a former deputy commissioner of the FDA under George W. Bush, will look to cut th red tape at the FDA, enabling the agency to approve drugs, particularly generic drugs, more quickly.
Before accepting the position, Gottlieb would have to to resign from the pharmaceutical boards, and get rid of stock in companies he’d regulate at FDA. Gottlieb also must be confirmed by the Senate before he takes over at the agency.
Scott Gottlieb is an American physician and conservative health policy analyst named in March 2017 as likely commissioner of the Food & Drug Administration (FDA) in President Donald Trump's administration.He is a clinical assistant professor at New York University School of Medicine, a resident fellow at the conservative American Enterprise Institute, and an internist at Tisch Hospital.
Gottlieb has worked in multiple roles for the Federal government of the United States, including Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration (FDA), in which capacity he served from 2005 to 2007. He helped initiate the early development of FDA's generic drug user fee program and the Agency's release of the Physician Labeling Rule.
He also worked on development of the FDA's policies related to the tentative approval of fixed dose combination drugs for the treatment of HIV/AIDS under the PEPFAR program. He was appointed to the Senior Executive Service and granted a top secret security clearance during his appointment as FDA's Deputy Commissioner for Medical and Scientific Affairs. He was also as a member of the White House Biodefense Interagency Working Group, which was convened after the September 11, 2001 attacks to help draft a strategic plan for the development of U.S. biodefense countermeasures. While working for the FDA, Gottlieb had to recuse himself from working on planning for a possible bird flu epidemic due to his ties to pharmaceutical companies. Before becoming the FDA's Deputy Commissioner, Gottlieb served as a senior advisor to the FDA Commissioner and as the FDA's Director of Medical Policy Development.
In 2013, Gottlieb was appointed by the Senate Minority Leader Mitch McConnell to serve as a member of the Federal Health IT Policy Committee which advises the U.S. Department of Health and Human Services and is responsible for making recommendations on the meaningful use standards as part of the HITECH Act. In 2016 members of President-elect Donald Trump's transition team said Trump was considering Gottlieb to head the FDA as its Commissioner. Gottlieb worked as an advisor to, and then a member of the Trump Transition Team starting from the Summer of 2016. He was previously a Senior Advisor to the 2016 Presidential campaign of Wisconsin Governor Scott Walker.
Read the Bloomberg coverage
Biography source: Edited from Wikipedia
Posted by Dr. Tim Sandle